FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MCENANY PATRICK J				<u>C</u>	2. Issuer Name and Ticker or Trading Symbol CATALYST PHARMACEUTICALS, INC. CPRX						<u>(Che</u>	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) 355 ALH	•	rst) CIRCLE, SUITE	(Middle) 801	12	3. Date of Earliest Transaction (Month/Day/Year) 12/08/2023						X Officer (give title below) Other (specify below) Chairman and CEO						
(Street) CORAL GABLES	s FI		33134	4.	4. If Amendment, Date of Original F				ed (Month/Da	ay/Year)	Line) X Form fi	oint/Group Filing (Check Applicated by One Reporting Person ed by More than One Reporting				
(City)	(S	tate)	(Zip)	R	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							to					
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transar Date (Month/Date				ansaction	action 2A. Deemed Execution Date,		3. Transaction	tr. 5)		ed (A) or tr. 3, 4 and	5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		. Nature f Indirect leneficial ownership nstr. 4)		
	7		re Securities Acquired, Disposed of, or Beneficially Owned s, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	Perivative Conversion Date Execution Date, Courity or Exercise (Month/Day/Year) if any		Code	ransaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly Di or (I)	o. wnership orm: irect (D) r Indirect (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Options to purchase common stock	\$14.15	12/08/2023		A		73,810		(1)	12/08/2030	Common Stock	73,810	\$0	3,001,47	17	D		
Restricted Stock Units	(2)	12/08/2023		A		10,601		(1)	(3)	Common Stock	10,601	\$0	3,012,07	78	D		

Explanation of Responses:

- 1. Derivative securities vest in equal tranches, 1/3rd on December 8, 2024, 1/3rd on December 8, 2025 and 1/3rd on December 8, 2026.
- 2. Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
- 3. Shares of common stock will be delivered to the Reporting Person upon vesting.

/s/ Patrick J. McEnany ** Signature of Reporting Person 12/12/2023

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.